The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options
Abstract
Summary: Secondary hyperparathyroidism (SHPT) is a challenge frequently encountered in the management of patients with chronic kidney disease (CKD). Downregulation of the parathyroid vitamin D and calcium-sensing receptors represent critical steps that lead to abnormalities in mineral metabolism: high phosphate, low calcium, and vitamin D deficiency. These imbalances result in parathyroid hyperplasia and contribute to vascular calcification. New studies have established a central role for fibroblast growth factor 23 (FGF-23) in the regulation of phosphate-vitamin D homeostasis. FGF-23 concentration increases in CKD and contributes to SHPT. Achieving current targets for the key mineral parameters in the management of SHPT set by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines can be challenging. This review summarizes the current understanding and evidence supporting strategies for SHPT treatment in CKD patients. Treatment should include a combination of dietary phosphorus restriction, phosphate binders, vitamin D sterols, and calcimimetics. Parathyroidectomy is effective in suitable candidates refractory to medical therapy and the standard against which new approaches should be measured. Future strategies may focus on the stimulation of apoptotic activity of hyperplastic parathyroid cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Block, G. A., Klassen, P. S., Lazarus, J. M., Ofsthun, N., Lowrie, E. G., & Chertow, G. M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000133041.27682.a2 · Cited by 2,687
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
Massry, S. G., Coburn, J. W., Chertow, G. M., Hruska, K. A., Langman, C. B., Malluche, H. H., Martin, K. J., McCann, L. M., McCarthy, J. T., Moe, S. M., et al. (2003) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 2,527
Self-citationMacLeod, A. M. (2009) · Kidney International · Cited by 2,218
Bone metabolism and disease in chronic kidney disease
Eknoyan, G., Levin, A., & Levin, N. W. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00905-3 · Cited by 1,286
The parathyroid is a target organ for FGF23 in rats
Ben-Dov, I. Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R., Kuro-o, M., Mohammadi, M., Sirkis, R., Naveh-Many, T., & Silver, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32409 · Cited by 951
Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy
Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J. M., & Thadhani, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022536 · Cited by 927
Block, G. A., Raggi, P., Bellasi, A., Kooienga, L., & Spiegel, D. M. (2007) · Kidney International · doi:10.1038/sj.ki.5002059 · Cited by 796
Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study
Teng, M., Wolf, M., Ofsthun, M. N., Lazarus, J. M., Hernán, M. A., Camargo, C. A., & Thadhani, R. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004070573 · Cited by 782
Fukuda, N., Tanaka, H., Tominaga, Y., Fukagawa, M., Kurokawa, K., & Seino, Y. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116720 · Cited by 596
Mechanisms of Vascular Calcification in Chronic Kidney Disease
Moe, S. M., & Chen, N. X. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007080854 · Cited by 579
Cited by
The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases
Hannan, F. M., Kallay, E., Chang, W., Brandi, M. L., & Thakker, R. V. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0115-0 · Cited by 394
Obesity and diabetes: An update
Verma, S., & Hussain, M. E. (2017) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2016.06.017 · Cited by 318
The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD)
Goldsmith, D. J. A., Massy, Z. A., & Brandenburg, V. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.10.002 · Cited by 21
Viklicky, O., Hruba, P., Tomiuk, S., Schmitz, S., Gerstmayer, B., Sawitzki, B., Miqueu, P., Mrazova, P., Tycova, I., Svobodova, E., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169624 · Cited by 12
Metadata
- Authors
- Cunningham, J., Locatelli, F., & Rodriguez, M.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2011-04
- Volume
- 6
- Issue
- 4
- Pages
- 913-921
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2136991956
- Cited by
- 646
- References
- 53
- FWCI
- 18.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options. https://app.cochat.ai/papers/10.2215/cjn.06040710
- The paper
- Cunningham, J., Locatelli, F., & Rodriguez, M. (2011). Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.06040710
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.